Abstract 2233
Background
In a pooled analysis of COMBI-d (NCT01584648) and COMBI-v (NCT01597908) trials, D+T led to long-term disease control in many pts and 5-y survival in approximately one-third of pts with BRAF V600–mutant unresectable or metastatic melanoma. In pts with resected BRAF V600–mutant stage III melanoma in COMBI-AD (NCT01682083), adjuvant D+T significantly improved relapse-free survival (RFS) with 3- and 4- year RFS rates of 59% and 54%, respectively. A higher rate of permanent discontinuation due to AEs was observed in the adjuvant setting in COMBI-AD (26%) than in the metastatic setting in COMBI-d/v (15%).
Methods
Analyses were performed using pt-level pooled data from COMBI-d and COMBI-v (phase III randomized trials comparing D+T with D+ placebo [PBO] or vemurafenib in unresectable or metastatic BRAF-mutant melanoma) and COMBI-AD (phase III, randomized, double-blind, PBO-controlled trial comparing adjuvant D+T with PBO in resectable stage III melanoma). In COMBI-d/v, pts were treated until disease progression; in COMBI-AD, pts were treated for 12 mo with adjuvant D+T. AEs were graded using CTCAE v4.0 and assessed over time using exposure-adjusted rates (occurrences/pt/3-mo exposure) calculated over 3-mo intervals.
Results
All-cause AE rates were 98% (548/559) in the metastatic and 97% (422/435) in the adjuvant setting. Grade (G) ≥ 3 AE rates were 57% (319/559) in COMBI-d/v and 41% (180/435) in COMBI-AD. Pyrexia was the most common AE in COMBI-d/v (any-grade [58%]; G ≥ 3 [6%]) and COMBI-AD (any-grade [63%]; G ≥ 3 [5%]). There were no treatment (tx)-related deaths in COMBI-d/v or COMBI-AD. In the first 3 mo of tx, the exposure-adjusted AE rates for any event in pts treated with D+T in the metastatic and adjuvant setting were 7.54 and 6.14, respectively. AE rates decreased with increased time on tx: 3 to < 6 mo (3.93 [COMBI-d/v]; 2.58 [COMBI-AD]); 6 to < 9 mo (3.22; 1.80); and 9 to < 12 mo (2.94; 1.65).
Conclusions
In the metastatic and adjuvant settings, there was a trend toward decreased AEs with longer tx duration. The rate of G ≥ 3 AEs was lower in the adjuvant vs metastatic setting suggesting that increased AE-related discontinuations in COMBI-AD are unlikely due to excess toxicity.
Clinical trial identification
NCT01584648 NCT01597908 NCT01682083.
Editorial acknowledgement
Allison Lytle, PhD, from ArticulateScience LLC, funded by Novartis Pharmaceuticals Corporation.
Legal entity responsible for the study
Novartis Pharmaceuticals Corporation.
Funding
Novartis Pharmaceuticals Corporation.
Disclosure
J.J. Grob: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Pfizer. V.G. Atkinson: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Serono; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Roche/Genentech; Travel / Accommodation / Expenses: OncoSec. C. Robert: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Array; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Merck. D. Schadendorf: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche/Genentech; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: Immunocore; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Incyte; Honoraria (self), Advisory / Consultancy: 4SC; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Advisory / Consultancy: Mologen; Advisory / Consultancy: Sanofi/Regeneron; Speaker Bureau / Expert testimony: Roche; Travel / Accommodation / Expenses: Merck; Honoraria (self): Sysmex; Honoraria (self): Grünenthal Group; Honoraria (self): Agenus; Honoraria (self): Array BioPharma; Honoraria (self): AstraZeneca; Honoraria (self): LEO Pharma; Honoraria (self): Pfizer; Honoraria (self): Philogen; Honoraria (self): Regeneron; Honoraria (self): Mologen. P. Nathan: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Immuncore; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: GlaxoSmithKline; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Merck. M.A. Davies: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy, Research grant / Funding (self): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (self): Genentech/Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Vaccinex; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Syndax; Advisory / Consultancy: NanoString Technologies; Advisory / Consultancy: Array BioPharma; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Merck; Research grant / Funding (self): Oncothyreon; Research grant / Funding (self): Myriad Genetics; Research grant / Funding (self): Sanofi. R. Kefford: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy: TEVA; Travel / Accommodation / Expenses: Bristol-Myers Squibb. R. Dummer: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy, Intermittent, project focused : Novartis; Advisory / Consultancy, Intermittent, project focused : Merck Sharp & Dhome; Advisory / Consultancy, Intermittent, project focused : Bristol-Myers Squibb; Advisory / Consultancy, Intermittent, project focused : Roche; Advisory / Consultancy, Intermittent, project focused : Amgen; Advisory / Consultancy, Intermittent, project focused : Takeda; Advisory / Consultancy, Intermittent, project focused : Pierre Fabre; Advisory / Consultancy, Intermittent, project focused : Sun Pharma; Advisory / Consultancy, Intermittent, project focused : Sanofi; Advisory / Consultancy, Intermittent, project focused: Catalym . J.M. Kirkwood: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Novartis; Advisory / Consultancy: Array BioPharma; Advisory / Consultancy, Research grant / Funding (institution): Immunocore; Advisory / Consultancy: Iovance; Advisory / Consultancy: Elsevier; Advisory / Consultancy: Checkmate Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Prometheus Laboratories. K.T. Flaherty: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Genentech; Advisory / Consultancy: Merck; Advisory / Consultancy: Lilly; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Oncoceutics; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Adaptimmune; Advisory / Consultancy: Aeglea Biotherapeutics; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Loxo; Advisory / Consultancy: Roche; Advisory / Consultancy: Asana Biosciences; Advisory / Consultancy: Incyte; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Shattuck Labs; Advisory / Consultancy: Tolero Pharmaceuticals; Advisory / Consultancy: Array BioPharma; Advisory / Consultancy, Shareholder / Stockholder / Stock options: FOGPharma; Advisory / Consultancy: Neon Therapeutics; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Tvardi; Advisory / Consultancy: Takeda; Advisory / Consultancy: Verastem; Advisory / Consultancy: Boston Biomedical; Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Advisory / Consultancy: Cell Medica; Advisory / Consultancy, Travel / Accommodation / Expenses: Debiopharm Group; Shareholder / Stockholder / Stock options: Clovis Oncology; Shareholder / Stockholder / Stock options: X4 Pharma; Shareholder / Stockholder / Stock options: Strata Oncology; Shareholder / Stockholder / Stock options: PIC Therapeutics; Shareholder / Stockholder / Stock options: Fount Therapeutics; Shareholder / Stockholder / Stock options: Apricity Health; Shareholder / Stockholder / Stock options: Vivid Biosciences; Shareholder / Stockholder / Stock options: Checkmate Pharmaceuticals. A. Ribas: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Advisory / Consultancy: Merck; Advisory / Consultancy: Amgen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Chugai Pharma; Shareholder / Stockholder / Stock options: Compugen; Shareholder / Stockholder / Stock options: FLX Bio; Shareholder / Stockholder / Stock options: CytomX Therapeutics; Shareholder / Stockholder / Stock options: Five Prime Therapeutics; Shareholder / Stockholder / Stock options: Advaxis; Shareholder / Stockholder / Stock options: Arcus Biosciences; Shareholder / Stockholder / Stock options: Tango Therapeutics; Shareholder / Stockholder / Stock options: PACT Pharma; Shareholder / Stockholder / Stock options: Merus; Shareholder / Stockholder / Stock options: Rgenix; Shareholder / Stockholder / Stock options: ImaginAb; Shareholder / Stockholder / Stock options: Lutris. P. Burgess: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Full / Part-time employment: Novartis; Shareholder / Stockholder / Stock options: GlaxoSmithKline. E. Gasal: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. G.V. Long: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: MERCK; Honoraria (self), Advisory / Consultancy: Novartis; Advisory / Consultancy: Array BioPharma; Advisory / Consultancy: Pierre Fabre.A. Hauschild: Non-remunerated activity/ies, Medical writing assistance: ArticulateScience LLC; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): MerckSerono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): MSD/Merck; Advisory / Consultancy, Research grant / Funding (institution): Philogen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pierre Fabre; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Provectus; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Regeneron; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy: OncoSec; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi-Genzyme; Advisory / Consultancy: Sun Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis Pharma.
Resources from the same session
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract